• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Adimab

edit

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Milestones

edit

• 
  Adimab added Tillman Gerngross as CEO.
  Posted 5/14/11 at 6:18pm
• 
  Adimab added Errik B. Anderson as COO.
  Posted 5/14/11 at 6:17pm
• 
  Adimab received $4M in Unattributed funding. (12/1/10)
  Posted 12/1/10 at 10:57pm via masshightech.com
• 
  Adimab received $3.18M in Series B funding. (4/1/08)
  Posted 2/24/10 at 3:59pm via sec.gov
• 
  Adimab received $5.9M in Series A funding. (9/21/07)
  Posted 2/24/10 at 3:57pm via sec.gov
• 
  Adimab received $400k in Series A funding. (7/1/07)
  Posted 2/24/10 at 3:57pm via sec.gov
• 
  Adimab received $2.38k in Unattributed funding. (7/16/07)
  Posted 2/24/10 at 3:57pm via sec.gov
• 
  Adimab received $4M in Series C funding. (11/20/08)
  Posted 1/22/10 at 4:28pm via adimab.com
• 
  Adimab received $8.2M in Series D funding. (1/22/10)
  Posted 1/22/10 at 4:28pm via onbiovc.com

Videos

Screenshots

edit

Sources

1. SEC D (sec.gov) [edit]
2. SEC D (sec.gov) [edit]
3. SEC D (sec.gov) [edit]
4. SEC D (sec.gov) [edit]
5. Adimab, Inc. Announces Series C Financing (adimab.com) [edit]
6. Adimab, Inc.: Series D $8.2M (onbiovc.com) [edit]
7. NH biotech startup Adimab attracts $4M funding (masshightech.com) [edit]